Innate Pharma Share Price Today

Innate Pharma Q3FY26 Results: Cash rises to €96.8 million, runway extends to Q1 2028

Cash position stands at €96.8 million as of September 30, 2026, with runway extended to Q1 2028. Nine-month revenue rose to €3.4 million from €2.3 million in the prior year period. IPH4502 dose-escalation data scheduled for presentation at ENA Symposium on November 18, 2026. Lacutamab Phase 3 TELLOMAK-3 trial expects first patient dosing in Q1 2027. CFO Frédéric Lombard to step down on December 31, 2026.

Innate Pharma H1FY26 Results: EPS $(0.24) misses estimate

Innate Pharma H1FY26 EPS of $(0.24) missed the $(0.16) estimate by 50%. Sales of $6.583 million missed the $9.100 million consensus estimate. Net loss narrowed 8% YoY to €19.6 million as operating expenses fell 18.5%. Sobi deal upfront payment and equity raise extend cash runway to Q1 2028.

Innate Pharma to host conference call and webcast on August 14

Innate Pharma SA will conduct a conference call on August 14, 2026, featuring key executives including CEO Jonathan Dickinson and CFO Frédéric Lombard. The clinical-stage biotech firm, listed on Euronext Paris and Nasdaq, will discuss its immunotherapy pipeline, which includes the lead ADC candidate IPH4502 and partnered assets lacutamab and monalizumab.

Innate Pharma shares surge 23.7% as Sobi deal secures $75m upfront for lacutamab

Innate Pharma SA announced a strategic partnership with Sobi to advance lacutamab for CTCL, securing a $75 million upfront payment. The deal includes up to $580 million in total potential payments and grants Sobi exclusive commercialization rights. Innate shares rose 23.7% following the announcement.

Innate Pharma to join BTIG bladder cancer panel discussion

Innate Pharma SA announced that Sonia Quaratino, EVP Chief Medical Officer, will participate in the panel discussion 'Changing Treatment Landscape in Bladder Cancer' at the BTIG Virtual Biotechnology Conference on July 28, 2026. The company is advancing a portfolio of immunotherapies, including IPH4502, lacutamab, and monalizumab, and has collaborations with Sanofi and AstraZeneca.

Innate Pharma completes Phase 1 enrollment for IPH4502 study

Innate Pharma SA has completed enrollment in the dose escalation phase of its IPH4502-101 study, a Phase 1 trial evaluating its proprietary Nectin-4 exatecan antibody-drug conjugate (ADC). The study recruited 76 patients with advanced solid tumors in France and the United States. Preliminary data from this cohort is expected by year-end and will guide the company's Phase 1 dose optimization in selected tumor types.